Evidence map›Paper›PMID 26818025›Full record

ArticleTechnology in cancer research & treatment2017

Customized Tool for the Validation of Optical Coherence Tomography in Differentiation of Prostate Cancer.

B G Muller, A Swaan, D M de Bruin, W van den Bos, A W Schreurs, D J Faber, E C H Zwartkruis, L Rozendaal, A N Vis, J A Nieuwenhuijzen and 3 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Technology in cancer research & treatment, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. The clinical usefulness of optical coherence tomography during cancer interventions.Journal of cancer research and clinical oncology · 2018
    Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

B G Muller1 Department of Urology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
A Swaan1 Department of Urology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
D M de Bruin1 Department of Urology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
W van den Bos1 Department of Urology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
A W Schreurs3 Department of Instrumental Services, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
D J Faber2 Department of Biomedical Engineering and Physics, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
E C H Zwartkruis4 Department of Pathology, VU University Medical Center, Free University, Amsterdam, the Netherlands.
L Rozendaal4 Department of Pathology, VU University Medical Center, Free University, Amsterdam, the Netherlands.
A N Vis5 Department of Urology, VU University Medical Center, Free University, Amsterdam, the Netherlands.
J A Nieuwenhuijzen5 Department of Urology, VU University Medical Center, Free University, Amsterdam, the Netherlands.
R J A van Moorselaar5 Department of Urology, VU University Medical Center, Free University, Amsterdam, the Netherlands.
T G van Leeuwen2 Department of Biomedical Engineering and Physics, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
J J M C H de la Rosette1 Department of Urology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
Academic Medical Center · NLAmsterdam UMC Location VUmc · NLUniversity of Amsterdam · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo design and demonstrate a customized tool to generate histologic sections of the prostate that directly correlate with needle-based optical coherence tomography pullback measurements. MATERIALS AND

methodsA customized tool was created to hold the prostatectomy specimens during optical coherence tomography measurements and formalin fixation. Using the tool, the prostate could be sliced into slices of 4 mm thickness through the optical coherence tomography measurement trajectory. In this way, whole-mount pathology slides were produced in exactly the same location as the optical coherence tomography measurements were performed. Full 3-dimensional optical coherence tomography pullbacks were fused with the histopathology slides using the 3-dimensional imaging software AMIRA, and images were compared.

resultsA radical prostatectomy was performed in a patient (age: 68 years, prostate-specific antigen: 6.0 ng/mL) with Gleason score 3 + 4 = 7 in 2/5 biopsy cores on the left side (15%) and Gleason score 3 + 4 = 7 in 1/5 biopsy cores on the right side (5%). Histopathology after radical prostatectomy showed an anterior located pT2cNx adenocarcinoma (Gleason score 3 + 4 = 7). Histopathological prostate slides were produced using the customized tool for optical coherence tomography measurements, fixation, and slicing of the prostate specimens. These slides correlated exactly with the optical coherence tomography images. Various structures, for example, Gleason 3 + 4 prostate cancer, stroma, healthy glands, and cystic atrophy with septae, could be identified both on optical coherence tomography and on the histopathological prostate slides.

conclusionWe successfully designed and applied a customized tool to process radical prostatectomy specimens to improve the coregistration of whole mount histology sections to fresh tissue optical coherence tomography pullback measurements. This technique will be crucial in validating the results of optical coherence tomography imaging studies with histology and can easily be applied in other solid tissues as well, for example, lung, kidney, breast, and liver. This will help improve the efficacy of optical coherence tomography in cancer detection and staging in solid organs.

Indexed as

Tomography, Optical CoherenceAgedAged, 80 and overBiomarkers, TumorBiopsyHumansImaging, Three-DimensionalMaleMiddle AgedNeoplasm GradingProstate-Specific AntigenProstatic NeoplasmsBiomarkers, TumorProstate-Specific Antigenhistopathologyneedle-basedoptical coherence tomographyprostatevalidation

Identifiers

PMID26818025
PMCPMC5616116
OpenAlexW2302849661

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.